These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29163826)

  • 1. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody
    Booth L; Roberts JL; Poklepovic A; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
    Oncotarget; 2017 Oct; 8(52):90262-90277. PubMed ID: 29163826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
    Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
    Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.
    Booth L; Roberts JL; Poklepovic A; Dent P
    Front Oncol; 2019; 9():650. PubMed ID: 31380285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
    Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.
    Dent P; Booth L; Roberts JL; Liu J; Poklepovic A; Lalani AS; Tuveson D; Martinez J; Hancock JF
    Oncogene; 2019 Jul; 38(30):5890-5904. PubMed ID: 31253872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
    Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
    Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.
    Booth L; Roberts JL; Rais R; Kirkwood J; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Oncotarget; 2018 Jan; 9(5):6062-6074. PubMed ID: 29464055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neratinib augments the lethality of [regorafenib + sildenafil].
    Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Hancock JF; Poklepovic A; Dent P
    J Cell Physiol; 2019 Apr; 234(4):4874-4887. PubMed ID: 30203445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palbociclib augments Neratinib killing of tumor cells that is further enhanced by HDAC inhibition.
    Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(2):157-168. PubMed ID: 30183517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling.
    Dent P; Booth L; Poklepovic A; Kirkwood JM
    Pigment Cell Melanoma Res; 2022 Jan; 35(1):66-77. PubMed ID: 34482636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells.
    Booth L; Roberts JL; Poklepovic A; Dent P
    Oncol Signal; 2018 Jun; 1(1):19-30. PubMed ID: 30740589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
    Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
    Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].
    Dent P; Booth L; Poklepovic A; Hoff DV; Hancock JF
    Cell Signal; 2020 Apr; 68():109525. PubMed ID: 31911180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling.
    Dent P; Booth L; Poklepovic A; Martinez J; Hoff DV; Hancock JF
    J Cell Physiol; 2020 Nov; 235(11):7889-7899. PubMed ID: 31912905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells.
    Roberts JL; Booth L; Poklepovic A; Dent P
    Front Oncol; 2021; 11():723966. PubMed ID: 34604061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
    Booth L; Poklepovic A; Dent P
    Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins.
    Booth L; West C; Moore RP; Von Hoff D; Dent P
    Front Oncol; 2021; 11():711043. PubMed ID: 34490108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cells.
    Booth L; Poklepovic A; Hancock JF; Dent P
    Anticancer Drugs; 2023 Oct; 34(9):1025-1034. PubMed ID: 37703296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells.
    Roberts JL; Poklepovic A; Booth L; Dent P
    Cell Signal; 2020 Jun; 70():109573. PubMed ID: 32087304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.